A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at. This offering is being made solely by means of a prospectus supplement and accompanying prospectus included in the registration statement. Securities and Exchange Commission ("SEC") and automatically became effective upon filing. The offering is expected to close on or about November 19, 2021, subject to satisfaction of customary closing conditions.Ī registration statement relating to these securities was filed with the U.S. Riley Securities and BTIG are acting as co-managers for the offering. Guggenheim Securities is also acting as a book-running manager for the offering.
Piper Sandler and Stifel are acting as the joint book-running managers for the offering. ViewRay intends to use the net proceeds from the offering for general corporate purposes, including working capital, capital expenditures, continued research and development and commercial expenses. In addition, ViewRay has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares to be sold in the offering will be offered by ViewRay. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the pricing of an underwritten public offering of 12,500,000 shares of common stock at a price to the public of $5.60 per share, for gross proceeds of $70 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay.
0 kommentar(er)
